BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Beth Israel Deaconess Medical Center · Harvard University · +28 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
524
total citations
- FWCI
- 24.98
- Percentile
- 100%
- References
- 27
Citations per year
Authors
26- BBBruno Bockorny
Beth Israel Deaconess Medical Center, Harvard University
- VSValerya Semenisty
Rambam Health Care Campus
- TMTeresa Macarulla
Hebron University, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
- EBErkut Borazanci
Translational Genomics Research Institute, HonorHealth
- BMBrian M. Wolpin
Harvard University, Dana-Farber Cancer Institute
Topics & keywords
Topics
Keywords
- Pembrolizumab
- Medicine
- Population
- Internal medicine
- Oncology
- Chemotherapy
- Pancreatic cancer
- Cohort
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.